
Sr. Research Associate, Novel Delivery Technologies
Your experience includes…
You are interested in…
About you:
Meet your Manager:
All inquiries regarding the posted position should be directed to the Talent Partner (see below). Interested individuals must apply directly to be considered for the opening.
Michael Monte – Principal Engineer, Novel Delivery Technologies
Michael is a member of the Novel Delivery Technologies team at Tessera where he focuses on developing targeted lipid nanoparticle delivery systems for delivery of RNA payloads to various extrahepatic cell types. Prior to joining Tessera, Michael previously worked on targeted LNP delivery and process development at Tidal Therapeutics and Sanofi. Michael holds an MS in Bioengineering from Tuft’s University and a BS in Chemical Engineering from Northeastern University.
Meet our Leadership Team and Board of Directors
Meet your Talent Partner:
Ben Hoogheem – Senior Director, Head of Talent Management
As Head of Talent Management at Tessera Therapeutics, Ben leads Tessera’s talent strategy across talent acquisition, performance management, and talent mobility.
Ben began his career as an in vivo Pharmacologist, which gave him a lasting appreciation for the rigor, creativity, and collaboration that drive scientific discovery. That foundation continues to shape how he helps build organizations designed to enable science thrive.
Ben is focused on aligning exceptional people with bold science – creating the structure, clarity, and culture that empower teams to scale effectively and achieve meaningful impact.
Compensation:
The stated pay range represents Tessera’s good-faith estimate for this role. Actual compensation will be determined based on a number of factors, including but not limited to individual qualifications, years of relevant experience, internal compensation alignment, and external market data.
Pay Range: $44.00 - $50.00 USD per hour
Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy.
More about Tessera Therapeutics:
Tessera is proud to be an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, age, sex, national origin, disability status, marital status, genetics, protected veteran status, citizenship status, sexual orientation, gender identity or expression, or any other characteristic identified by federal, state, or local laws where we operate. Tessera provides reasonable accommodations to qualified applicants and employees with disabilities. To begin an interactive dialogue with Tessera regarding a reasonable accommodation in connection with the hiring process and/or to perform the essential functions of the position for which the applicant has applied, please contact the recruiter or Accommodations@tesseratx.com
Recruitment & Staffing Agencies: Tessera Therapeutics does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Tessera Therapeutics or its employees is strictly prohibited unless contacted directly by Tessera Therapeutics’ internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of Tessera Therapeutics, and Tessera Therapeutics will not owe any referral or other fees with respect thereto.

Tessera Therapeutics is a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, with the aim to unlock broad new therapeutic frontiers.
Our mission is to cure disease by writing in the code of life. We believe our Gene Writing™ and delivery platforms will enable transformative genetic medicines to treat monogenic diseases, cancer and potentially autoimmune and other diseases.
Discover your future at Tessera.